You can buy or sell LABP and other stocks, options, and ETFs commission-free!
Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway.
52 Week High
52 Week Low
— per share
Expected Jun 8, Pre-Market